Home » Alpha 1 Lung Diseases Market

Alpha 1 Lung Diseases Market By Diagnostics (Genetic Testing, Pulmonary Function Testing (PFT), Liver Function Testing, Imaging) By Treatments (Alpha-1 Augmentation Therapy, Bronchodilators, Anti-inflammatory Drugs, Supplemental Oxygen, Pulmonary Rehabilitation, Liver Disease Management) By Patient Support and Services (Patient Education, Patient Advocacy Organizations, Telehealth and Remote Monitoring, Psychosocial Support, Home Healthcare Services) By Research and Development (Drug Development, Clinical Trials, Genetic Research) By End Users (Hospitals and Clinics, Pharmaceutical Companies, Patient Community, Research Institutions) By Region – Growth, Future Prospects & Competitive Analysis, 2022 – 2030

Price: $4999

Published: | Report ID: 30930 | Report Format : PDF

Market Insights

  • The global demand for Alpha 1 Lung Diseases was valued at USD 5184.5 Million in 2022 and is expected to reach USD 21560.0 Million in 2030, growing at a CAGR of 19.50% between 2023 and 2030.
  • The major market category is genetic testing.
  • The market demand category is Alpha-1 Augmentation Therapy, and the market’s fastest-growing sector is Pulmonary Rehabilitation.
  • Patient Advocacy Organizations are a significant component of the Alpha 1 Lung Disease market, as is Telehealth and remote monitoring.
  • Genetic research is a popular category.
  • The hospital and clinics segment dominates the market, while pharmaceutical corporations possess the majority of the stock.
  • North America is likely to be the largest market during the forecast period, accounting for more than 45% of the market share in 2022, while the Asia Pacific Alpha 1 Lung Disease Market is expected to grow the fastest.
  •  Increased R&D activities to accelerate market growth
  • Huge R&D investments are being made to stifle market expansion.

Alpha 1 Lung Diseases Market

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Executive Summary

Market Definition

The Alpha 1 Lung Disease Market is the industry and domain that focuses on the diagnosis, treatment, and management of illnesses caused by alpha-1 antitrypsin (AAT) deficiency, which is a common inherited genetic disorder. It includes mostly of medicines and pharmaceuticals used to treat alpha-1 lung disorders such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, liver cirrhosis, and bronchiectasis. Treatment options include alpha-1 proteinase inhibitor augmentation, gene therapy, lung transplantation, and supportive medicines such as oxygen and bronchodilators. Pharmaceutical firms, medical device manufacturers, hospitals, specialty clinics, research organizations, distributors, and other entities involved in the development and commercialization of medicines for patients with alpha-1 lung disease make up the market.

Market Overview

The global -+has witnessed steady growth in recent years and is expected to grow at a CAGR of 19.50% between 2023 and 2030. The market was valued at USD 5184.5 million in 2022 and is expected to reach USD 21560.0 million in 2030.

Alpha-1 antitrypsin deficiency (Alpha-1) is a hereditary illness that can cause lung and liver damage. While there are therapies and assistance available for people with Alpha-1, it is not considered a separate market. Instead, the emphasis is on providing medical care, therapies, and support services to those suffering from the condition.

The increased prevalence of alpha-1 lung illnesses, rising detection rates, 47robust research pipelines, new product introductions, and expanding awareness are driving growth. Because of their high awareness and favourable reimbursement, North America and Europe are the largest markets.

Segmentation by Diagnostics

  • Genetic testing is the market’s dominant category. It has gained popularity in recent years because to its numerous uses in industries such as healthcare, agriculture, and forensics. Genetic testing aids in the identification of genetic abnormalities, the prediction of illness risks, and even the determination of ancestry. It has transformed our understanding of and approach to customized medicine.

Segmentation by Treatments

  • Alpha-1 Augmentation Therapy is the market demand segment. This therapy involves replenishing the defective alpha-1 antitrypsin protein in order to delay the course of lung illness. It is an important therapy option for those with Alpha-1 Antitrypsin Deficiency (AATD).
  • Pulmonary Rehabilitation is the market’s fastest-growing sector.

Segmentation by Patient Support and Services

  • Patient Advocacy Organizations are a major component in the Alpha 1 Lung Disease market. These organizations offer assistance, resources, and advocacy to people living with Alpha-1 and their families. They are critical in increasing awareness, fostering research, and linking patients with useful information and services.
  • Telehealth and remote monitoring is another market-dominant category. Telehealth has grown in popularity as technology has advanced, allowing patients to get healthcare services such as consultations, monitoring, and follow-ups remotely.

Segmentation by Research and Development

  • In the Alpha 1 Lung Disease market, Genetic Research is a popular category. The Alpha-1 Antitrypsin Deficiency gene, for example, is being studied as a genetic component associated with Alpha 1 Lung Disease.

Segmentation by End Users

  • The hospital and clinics segment dominates the market. In underdeveloped nations, hospitals are favoured for the treatment of AATD. This is due to the introduction of multispecialty healthcare in several nations, as well as increased investments in the healthcare sector by commercial and public entities.
  • Pharmaceutical companies own the majority of the stock. These firms are critical in the development and manufacture of drugs and therapies for the treatment of Alpha 1 Lung Disease. They invest in research and development in order to provide patients with cutting-edge medicines.
  • The Patient Community is another significant market category. Individuals with Alpha 1 Lung Disease and their relatives comprise the patient community.

Segmentation by Region

  • North America is predicted to be the biggest market during the forecast period, accounting for more than 45% of the market share in 2022.
  • The Asia Pacific Alpha 1 Lung Disease Market is expected to develop the fastest.
  • The rest of the world, including Latin America, the Middle East, and Africa, supplies the remaining demand for Alpha 1 Lung Disease.

Alpha 1 Lung Diseases Market Research

North America currently dominates the worldwide alpha-1 antitrypsin deficiency (AATD) augmentation treatment market and will do so during the projection period. The dominance of North America is owing to the rising frequency of AATD in the United States and Canada, as well as the strategic presence of significant corporations in the area.

Awareness campaigns in each area that focus on the diagnosis and treatment of AATD are critical to success, which will drive market expansion during the projection period.

Changes in legislation and conditions at the national level will have an impact on the market’s future and continuing developments. Country demographics, reimburse scenarios, new medication approval, and illness epidemiology are major factors that can forecast different nations’ market scenarios.

In addition, the Asia Pacific market is expanding primarily as a result of increased birth rates in emerging nations. Government initiatives in the identification and treatment of genetic diseases and severe illnesses are aiding the Asia Pacific market’s rapid growth. During the projection period, this is likely to create a significant opportunity for market participants.

Key Highlights of the Report

The global Alpha 1 Lung Disease Market is segmented by Diagnostics, Treatments, Patient Support and Servicess, Research and Development, End Users, Emerging Applications and region. Alpha-1 Augmentation Therapy is the market demand segment. In addition, the hospital and clinics segment leads the industry, and genetic research is a major category. Also, pulmonary rehabilitation is the market’s fastest-growing sector, with North America leading the market growth.

The primary drivers of the market include increased awareness and diagnosis of Alpha-1 antitrypsin deficiency, advancements in treatment choices and treatments for Alpha-1 lung disease, and a growing emphasis on personalized medicine and targeted therapies. Furthermore, the market is hampered by a lack of specialist treatment centres for Alpha-1 lung illness, the high cost of therapy and pharmaceuticals for Alpha-1 lung disease, and difficulties in early identification and diagnosis of Alpha-1 antitrypsin deficiency.

Nonetheless, North America presently dominates the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market and will continue to do so during the forecast period.

What Are The Main Drivers Of The Global Alpha 1 Lung Disease Market?

The rising awareness and diagnosis of Alpha-1 antitrypsin deficiency is one of the primary drivers in the Alpha 1 Lung Disease Market. As more healthcare professionals and individuals become aware of this genetic condition, early detection and intervention become possible. Another motivator is progress in therapy options and medicines for Alpha-1 lung disease. Ongoing research and development efforts have resulted in novel medicines aimed at managing symptoms and improving the quality of life for people suffering from Alpha-1 lung disease. Furthermore, there is a rising emphasis on personalized medicine and targeted medicines, which enable more individualized treatment approaches based on unique patient characteristics.

What Are The Major Challenges Faced By The Global Alpha 1 Lung Disease Market?

While there have been some good improvements, the Alpha 1 Lung Disease Market is not without its challenges. One of these is the scarcity and inaccessibility of specialized Alpha-1 lung disease treatment centres. Because not all locations may have specific centres or healthcare specialists with competence in managing this illness, access to proper care may be hampered. Furthermore, the high cost of therapy and drugs for Alpha-1 lung disease can be a substantial financial barrier for many people. The costs of continued therapy and drugs can be too expensive for individuals and their families.

What Are The Growth Opportunities In The Global Alpha 1 Lung Disease Market?

The Alpha 1 Lung Disease Market offers several chances. Innovative medicines and interventions for Alpha-1 lung disease continue to be the focus of research and development efforts. This opens up the possibility of developing more effective medicines that might better control symptoms and decrease disease progression. Collaborations and partnerships among healthcare professionals and organizations are increasingly increasing, with the goal of improving patient care and support. These collaborations may result in the exchange of information, resources, and best practices, which will eventually help people with Alpha-1 lung disease.

Market Drivers

The global Alpha 1 Lung Disease Market is driven by several factors. The following are the key drivers of the global Alpha 1 Lung Disease Market:

Increasing R&D Activities

The growing number of strategic alliances between public and private market actors is driving a rise in R&D efforts on a daily basis. These capabilities are being applied to the development of novel medications and medical technologies, which will increase the need for alpha1-antitrypsin deficiency treatment.

Furthermore, an increase in the number of genetic testing, blood tests, and biopsy tests, as well as increasing efforts by public and private groups to promote awareness, would all contribute to the market’s growth rate. Other reasons, such as rising demand for effective medications and greater usage of early diagnostic methods, will boost the market’s growth pace.

Market Restraints

The global Alpha 1 Lung Disease Marketfaces some challenges that may hinder its growth. These include the following:

Huge R&D Investments

High costs associated with R&D capabilities will emerge as one of the market’s most significant constraints. The lack of information and infrastructure in underdeveloped and backward countries, as well as slow diagnosis rates of alpha1-antitrypsin deficiency, may further stymie market growth. The slow speed of drug and inhibitor approval, the paucity of plasma fractionation capacity, and the increasing number of patent expirations will all provide hurdles to the market’s growth rate.

Opportunities

The global Alpha 1 Lung Disease Market offers significant growth opportunities. These include the following:

Personalized Medicine

The prospect for individualized medication is one intriguing opportunity in the Alpha 1 Lung Disease industry. With advances in genetic research and understanding of the Alpha-1 Antitrypsin Deficiency gene, there is a chance to develop personalized therapy for specific individuals. Personalized medicine takes a patient’s unique genetic makeup and traits into account in order to provide more effective and precise treatments. This strategy has the potential to improve patient outcomes, reduce side effects, and optimize treatment programs.

Healthcare practitioners can identify persons at high risk for Alpha 1 Lung Disease and adopt preventive treatments early on by leveraging genetic testing and analysis. Furthermore, personalized medicine can enable the creation of novel medicines that address specific genetic variants linked to disease. This strategy has the potential to enhance illness management, increase patient quality of life, and potentially save healthcare costs by avoiding useless medicines.

Competitive Landscape

Alpha 1 Lung Diseases Market Report

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key Players

The global Alpha 1 Lung Disease Market is highly competitive, with several key players. Some of the major players in the market and their market share are as follows:

  • AstraZeneca
  • Boehringer Ingelheim
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • CSL Behring
  • Vertex Pharmaceuticals
  • Amgen
  • Sanofi
  • GlaxoSmithKline
  • Gilead Sciences
  • Eli Lilly, AbbVie
  • Johnson & Johnson
  • Teva Pharmaceutical
  • Audentes Therapeutics
  • Regeneron Pharmaceuticals

These organizations prioritize product innovation, distribution channel expansion, and mergers and acquisitions to stay competitive.

The global Alpha 1 Lung Disease Market’s key players continually seek to stay ahead by offering new products and developments.

In October 2022, Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for a total estimated value of US$ 22 Million. This award assures that such products will continue to be sold in Canada.

In 2022, Kamada has announced the European launch of an inhaled form of its alpha-1 proteinase inhibitor Glassia. The medicine is likely to enhance results for people with alpha-1.

In 2021, Livmarli, a novel medicine developed by Takeda, has been approved by the FDA to treat alpha-1 antitrypsin insufficiency. Livmarli inhibits the buildup of aberrant alpha-1 protein in the liver.

Summary of Key Findings

  • Huge R&D efforts are being made to stymie market growth.
  • Market segmented by Diagnostics, Treatments, Patient Support and Services, Research and Development, End Users, and region.
  • The market demand category is Alpha-1 Augmentation Therapy,
  • Patient Advocacy Organizations are a significant component of the Alpha 1 Lung Disease market.
  • North America is leading market growth; the market is highly competitive with key players including AstraZeneca, Boehringer Ingelheim, Roche , Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical

Future Outlook

  • Increasing awareness and diagnosis
  • Treatment options advancements
  • New therapy research and development
  • Collaborations and partnerships to improve patient care
  • Emphasis on personalized medicine and focused therapeutics
  • Expanding patient and caregiver support networks

How CXOs Can Benefit from the Credence Research Alpha 1 Lung Disease Market Report

The Credence Research Alpha 1 Lung Disease Market Report provides CXOs with a comprehensive overview of the market, including:

  • Market size and growth forecast: The report provides detailed estimates of the global Alpha 1 Lung Disease Market size, segmented by by Diagnostics, Treatments, Patient Support and Services, Research and Development, End Users, and region. It also includes forecasts for the market through 2032, based on key trends and drivers.
  • Market segmentation: The report segments the Alpha 1 Lung Disease Market by global Alpha 1 Lung Disease Market size, segmented by by Diagnostics, Treatments, Patient Support and Services, Research and Development, End Users, and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
  • Competitive landscape: The report profiles the key players in the Alpha 1 Lung Disease Market and provides insights into their strategies, product offerings, and financial performance. This information can help CXOs to identify and assess their competition.
  • Key trends and drivers: The report identifies and analyzes the key trends and drivers that are shaping the Alpha 1 Lung Disease Market. This information can help CXOs to make informed decisions about their investments and strategies.

CXOs can use the insights from the Credence Research Alpha 1 Lung Disease Market Report to:

  • Identify growth opportunities: The report can help CXOs to identify new growth opportunities in the Alpha 1 Lung Disease Market. For example, it may highlight the potential for expanding telehealth services to reach more patients and provide convenient healthcare options.
  • Make informed investment decisions: The report can help CXOs to make informed investment decisions about Alpha 1 Lung Disease. For example, it may provide insights into the latest advancements in treatment options, such as gene therapies or targeted medications.
  • Develop competitive strategies: The report can help CXOs to develop competitive strategies for their Alpha 1 Lung Disease businesses. For example, it can provide valuable information on market dynamics, customer preferences, and competitor analysis.
  • Track market developments: The report can help CXOs to track market developments and stay ahead of the curve. For example, the report can provide CXOs with real-time updates and analysis on market trends, competitor activities, and regulatory changes in the Alpha 1 Lung Disease industry.

Overall, the Credence Research Alpha 1 Lung Disease Market Report is a valuable resource for CXOs who are looking to gain a deeper understanding of the market and identify opportunities for growth.

Segmentation

By Diagnostics:

  • Genetic Testing
  • Pulmonary Function Testing (PFT)
  • Liver Function Testing
  • Imaging

By Treatments:

  • Alpha-1 Augmentation Therapy
  • Bronchodilators
  • Anti-inflammatory Drugs
  • Supplemental Oxygen
  • Pulmonary Rehabilitation
  • Liver Disease Management

By Patient Support and Services:

  • Patient Education
  • Patient Advocacy Organizations
  • Telehealth and Remote Monitoring
  • Psychosocial Support
  • Home Healthcare Services

By Research and Development:

  • Drug Development
  • Clinical Trials
  • Genetic Research

By End Users:

  • Hospitals and Clinics
  • Pharmaceutical Companies
  • Patient Community
  • Research Institutions
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • South-east Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East and Africa

Table of Content
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Alpha 1 Lung Disease Market
2.1.1. Global Alpha 1 Lung Disease Market, By Diagnostics
2.1.2. Global Alpha 1 Lung Disease Market, By Treatments
2.1.3. Global Alpha 1 Lung Disease Market, By Patient Support and Services
2.1.4. Global Alpha 1 Lung Disease Market, By Research and Development
2.1.5. Global Alpha 1 Lung Disease Market, By End Users
2.1.6. Global Alpha 1 Lung Disease Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Alpha 1 Lung Disease Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Alpha 1 Lung Disease Market Drivers
3.2.2. Alpha 1 Lung Disease Market Restraints
3.2.3. Alpha 1 Lung Disease Market Opportunities
3.2.4. Major Alpha 1 Lung Disease Market Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Diagnostics
3.5.2. Treatments
3.5.3. Patient Support and Services
3.5.4. Research and Development
3.5.5. End Users
3.5.6. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2022
4.1.1. Global Alpha 1 Lung Disease Market: Company Market Share, Value 2022
4.1.2. Global Alpha 1 Lung Disease Market: Top 6 Company Market Share, Value 2022
4.1.3. Global Alpha 1 Lung Disease Market: Top 3 Company Market Share, Value 2022
4.2. Global Alpha 1 Lung Disease Market: Company Revenue Share Analysis, 2022
4.3. Company Assessment Metrics, 2022
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2022
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Type Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Type Matrix
4.7. Potential for New Players in the Global Alpha 1 Lung Disease Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2022
6.1. Company market share of key players, 2022
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Type Launch
6.5.5. Geographical Expansion
6.5.6. Autoimmune Diseases
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Alpha 1 Lung Disease Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Type Mix
7.2.4. Reduced Research and development Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Alpha 1 Lung Disease Market, By Diagnostics
8.1. Global Alpha 1 Lung Disease Market Overview, By Diagnostics
8.1.1. Global Alpha 1 Lung Disease Market Revenue Share, By Diagnostics, 2022 Vs 2030 (in %)
8.2. Genetic Testing
8.2.1. Global Alpha 1 Lung Disease Market, By GENETIC TESTING, By Region, 2017-2030 (US$ Mn)
8.2.2. Market Dynamics for GENETIC TESTING
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Pulmonary Function Testing (PFT)
8.3.1. Global Alpha 1 Lung Disease Market, By Pulmonary Function Testing (PFT), By Region, 2017-2030 (US$ Mn)
8.3.2. Market Dynamics for Pulmonary Function Testing (PFT)
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Liver Function Testing
8.4.1. Global Alpha 1 Lung Disease Market, By Liver Function Testing, By Region, 2017-2030 (US$ Mn)
8.4.2. Market Dynamics for Liver Function Testing
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Imaging
8.5.1. Global Alpha 1 Lung Disease Market, By Imaging, By Region, 2017-2030 (US$ Mn)
8.5.2. Market Dynamics for Imaging
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
9. Global Alpha 1 Lung Disease Market, By Treatments
9.1. Global Alpha 1 Lung Disease Market Overview, By Treatments
9.1.1. Global Alpha 1 Lung Disease Market Revenue Share, By Treatments, 2022 Vs 2030 (in %)
9.2. Alpha-1 Augmentation Therapy
9.2.1. Global Alpha 1 Lung Disease Market, By Alpha-1 Augmentation Therapy, By Region, 2017-2030 (US$ Mn)
9.2.2. Market Dynamics for Alpha-1 Augmentation Therapy
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Bronchodilators
9.3.1. Global Alpha 1 Lung Disease Market, By Bronchodilators, By Region, 2017-2030 (US$ Mn)
9.3.2. Market Dynamics for Bronchodilators
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Anti-inflammatory Drugs
9.4.1. Global Alpha 1 Lung Disease Market, By Anti-inflammatory Drugs, By Region, 2017-2030 (US$ Mn)
9.4.2. Market Dynamics for Anti-inflammatory Drugs
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. Supplemental Oxygen
9.5.1. Global Alpha 1 Lung Disease Market, By Supplemental Oxygen, By Region, 2017-2030 (US$ Mn)
9.5.2. Market Dynamics for Supplemental Oxygen
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
9.6. Pulmonary Rehabilitation
9.6.1. Global Alpha 1 Lung Disease Market, By Pulmonary Rehabilitation, By Region, 2017-2030 (US$ Mn)
9.6.2. Market Dynamics for Pulmonary Rehabilitation
9.6.2.1. Drivers
9.6.2.2. Restraints
9.6.2.3. Opportunities
9.6.2.4. Trends
9.7. Liver Disease Management
9.7.1. Global Alpha 1 Lung Disease Market, By Liver Disease Management, By Region, 2017-2030 (US$ Mn)
9.7.2. Market Dynamics for Liver Disease Management
9.7.2.1. Drivers
9.7.2.2. Restraints
9.7.2.3. Opportunities
9.7.2.4. Trends
10. Global Alpha 1 Lung Disease Market, By Patient Support and Services
10.1. Global Alpha 1 Lung Disease Market Overview, By Patient Support and Services
10.1.1. Global Alpha 1 Lung Disease Market Revenue Share, By Patient Support and Services, 2022 Vs 2030 (in %)
10.2. Patient Education
10.2.1. Global Alpha 1 Lung Disease Market, By Patient Education, By Region, 2017-2030 (US$ Mn)
10.2.2. Market Dynamics for Patient Education
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Patient Advocacy Organizations
10.3.1. Global Alpha 1 Lung Disease Market, By Patient Advocacy Organizations, By Region, 2017-2030 (US$ Mn)
10.3.2. Market Dynamics for Patient Advocacy Organizations
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Telehealth and Remote Monitoring
10.4.1. Global Alpha 1 Lung Disease Market, By Telehealth and Remote Monitoring, By Region, 2017-2030 (US$ Mn)
10.4.2. Market Dynamics for Telehealth and Remote Monitoring
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
10.5. Psychosocial Support
10.5.1. Global Alpha 1 Lung Disease Market, By Psychosocial Support, By Region, 2017-2030 (US$ Mn)
10.5.2. Market Dynamics for Psychosocial Support
10.5.2.1. Drivers
10.5.2.2. Restraints
10.5.2.3. Opportunities
10.5.2.4. Trends
10.6. Home Healthcare Services
10.6.1. Global Alpha 1 Lung Disease Market, By Home Healthcare Services, By Region, 2017-2030 (US$ Mn)
10.6.2. Market Dynamics for Home Healthcare Services
10.6.2.1. Drivers
10.6.2.2. Restraints
10.6.2.3. Opportunities
10.6.2.4. Trends
11. Global Alpha 1 Lung Disease Market, By Research and Development
11.1. Global Alpha 1 Lung Disease Market Overview, by Research and Development
11.1.1. Global Alpha 1 Lung Disease Market Revenue Share, By Research and Development, 2022 Vs 2030 (in %)
11.2. Drug Development
11.2.1. Global Alpha 1 Lung Disease Market, By Drug Development, By Region, 2017-2030 (US$ Mn)
11.2.2. Market Dynamics for Drug Development
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Clinical Trials
11.3.1. Global Alpha 1 Lung Disease Market, By Clinical Trials, By Region, 2017-2030 (US$ Mn)
11.3.2. Market Dynamics for Clinical Trials
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. Genetic Research
11.4.1. Global Alpha 1 Lung Disease Market, By Genetic Research, By Region, 2017-2030 (US$ Mn)
11.4.2. Market Dynamics for Genetic Research
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
12. Global Alpha 1 Lung Disease Market, By End Users
12.1. Global Alpha 1 Lung Disease Market Overview, By End Users
12.1.1. Global Alpha 1 Lung Disease Market Revenue Share, By End Users, 2022 Vs 2030 (in %)
12.2. Hospitals and Clinics
12.2.1. Global Alpha 1 Lung Disease Market, By Hospitals and Clinics, By Region, 2017-2030 (US$ Mn)
12.2.2. Market Dynamics for Hospitals and Clinics
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Pharmaceutical Companies
12.3.1. Global Alpha 1 Lung Disease Market, By Pharmaceutical Companies, By Region, 2017-2030 (US$ Mn)
12.3.2. Market Dynamics for Pharmaceutical Companies
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
12.4. Patient Community
12.4.1. Global Alpha 1 Lung Disease Market, By Patient Community, By Region, 2017-2030 (US$ Mn)
12.4.2. Market Dynamics for Patient Community
12.4.2.1. Drivers
12.4.2.2. Restraints
12.4.2.3. Opportunities
12.4.2.4. Trends
12.5. Research Institutions
12.5.1. Global Alpha 1 Lung Disease Market, By Research Institutions, By Region, 2017-2030 (US$ Mn)
12.5.2. Market Dynamics for Research Institutions
12.5.2.1. Drivers
12.5.2.2. Restraints
12.5.2.3. Opportunities
12.5.2.4. Trends
13. Global Alpha 1 Lung Disease Market, By Region
13.1. Global Alpha 1 Lung Disease Market Overview, by Region
13.1.1. Global Alpha 1 Lung Disease Market, By Region, 2022 vs 2030 (in%)
13.2. Diagnostics
13.2.1. Global Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030 (US$ Mn)
13.3. Treatments
13.3.1. Global Alpha 1 Lung Disease Market, By Treatments, 2017-2030 (US$ Mn)
13.4. Patient Support and Services
13.4.1. Global Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030 (US$ Mn)
13.5. Research and Development
13.5.1. Global Alpha 1 Lung Disease Market, By Research and Development, 2017-2030 (US$ Mn)
13.6. End Users
13.6.1. Global Alpha 1 Lung Disease Market, By End Users, 2017-2030 (US$ Mn)
14. North America Alpha 1 Lung Disease Market Analysis
14.1. Overview
14.1.1. Market Dynamics for North America
14.1.1.1. Drivers
14.1.1.2. Restraints
14.1.1.3. Opportunities
14.1.1.4. Trends
14.2. North America Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. North America Alpha 1 Lung Disease Market, By Treatments, 2017-2030(US$ Mn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. North America Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030(US$ Mn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. North America Alpha 1 Lung Disease Market, By Research and Development, 2017-2030(US$ Mn)
14.5.1. Overview
14.5.2. SRC Analysis
14.6. North America Alpha 1 Lung Disease Market, By End Users, 2017-2030(US$ Mn)
14.6.1. Overview
14.6.2. SRC Analysis
14.7. North America Alpha 1 Lung Disease Market, by Country, 2017-2030(US$ Mn)
14.7.1. North America Alpha 1 Lung Disease Market, by Country, 2022 Vs 2030 (in%)
14.7.2. U.S.
14.7.3. Canada
14.7.4. Mexico
15. Europe Alpha 1 Lung Disease Market Analysis
15.1. Overview
15.1.1. Market Dynamics for North America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. Europe Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Europe Alpha 1 Lung Disease Market, By Treatments, 2017-2030(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Europe Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Europe Alpha 1 Lung Disease Market, By Research and Development, 2017-2030(US$ Mn)
15.5.1. Overview
15.5.2. SRC Analysis
15.6. Europe Alpha 1 Lung Disease Market, By End Users, 2017-2030(US$ Mn)
15.6.1. Overview
15.6.2. SRC Analysis
15.7. Europe Alpha 1 Lung Disease Market, by Country, 2017-2030 (US$ Mn)
15.7.1. Europe Alpha 1 Lung Disease Market, by Country, 2022 Vs 2030 (in%)
15.7.2. UK
15.7.3. France
15.7.4. Germany
15.7.5. Italy
15.7.6. Spain
15.7.7. Benelux
15.7.8. Russia
15.7.9. Rest of Europe
16. Asia Pacific Alpha 1 Lung Disease Market Analysis
16.1. Overview
16.1.1. Market Dynamics for North America
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Asia Pacific Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Asia Pacific Alpha 1 Lung Disease Market, By Treatments, 2017-2030(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Asia Pacific Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Asia Pacific Alpha 1 Lung Disease Market, By Research and Development, 2017-2030(US$ Mn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. Asia Pacific Alpha 1 Lung Disease Market, By End Users, 2017-2030(US$ Mn)
16.6.1. Overview
16.6.2. SRC Analysis
16.7. Asia Pacific Alpha 1 Lung Disease Market, by Country, 2017-2030 (US$ Mn)
16.7.1. Asia Pacific Alpha 1 Lung Disease Market, by Country, 2022 Vs 2030 (in%)
16.7.2. China
16.7.3. Japan
16.7.4. India
16.7.5. South Korea
16.7.6. South East Asia
16.7.7. Rest of Asia Pacific
17. Latin America Alpha 1 Lung Disease Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Latin America Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Latin America Alpha 1 Lung Disease Market, By Treatments, 2017-2030(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Latin America Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Latin America Alpha 1 Lung Disease Market, By Research and Development, 2017-2030(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Latin America Alpha 1 Lung Disease Market, By End Users, 2017-2030(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. Latin America Alpha 1 Lung Disease Market, by Country, 2017-2030 (US$ Mn)
17.7.1. Latin America Alpha 1 Lung Disease Market, by Country, 2022 Vs 2030 (in%)
17.7.2. Brazil
17.7.3. Argentina
17.7.4. Rest of Latin America
18. Middle East Alpha 1 Lung Disease Market Analysis
18.1. Overview
18.1.1. Market Dynamics for North America
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Middle East Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Middle East Alpha 1 Lung Disease Market, By Treatments, 2017-2030(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Middle East Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Middle East Alpha 1 Lung Disease Market, By Research and Development, 2017-2030(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Middle East Alpha 1 Lung Disease Market, By End Users, 2017-2030(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Middle East Alpha 1 Lung Disease Market, by Country, 2017-2030 (US$ Mn)
18.7.1. Middle East Alpha 1 Lung Disease Market, by Country, 2022 Vs 2030 (in%)
18.7.2. UAE
18.7.3. Saudi Arabia
18.7.4. Rest of Middle East
19. Africa Alpha 1 Lung Disease Market Analysis
19.1. Overview
19.1.1. Market Dynamics for North America
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Africa Alpha 1 Lung Disease Market, By Diagnostics, 2017-2030(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Africa Alpha 1 Lung Disease Market, By Treatments, 2017-2030(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2030(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Africa Alpha 1 Lung Disease Market, By Research and Development, 2017-2030(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Africa Alpha 1 Lung Disease Market, By End Users, 2017-2030(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Africa Alpha 1 Lung Disease Market, by Country, 2017-2030 (US$ Mn)
19.7.1. Middle East Alpha 1 Lung Disease Market, by Country, 2022 Vs 2030 (in%)
19.7.2. South Africa
19.7.3. Egypt
19.7.4. Rest of Africa
20. Company Profiles
20.1. AstraZeneca,.
20.1.1. Company Overview
20.1.2. Types/Services Portfolio
20.1.3. Geographical Presence
20.1.4. SWOT Analysis
20.1.5. Financial Summary
20.1.5.1. Market Revenue and Net Profit (2019-2022)
20.1.5.2. Business Segment Revenue Analysis
20.1.5.3. Geographical Revenue Analysis
20.2. Boehringer Ingelheim,
20.3. Roche.
20.4. Novartis,.
20.5. Pfizer,.
20.6. Merck,.
20.7. Bristol-Myers Squibb,.
20.8. Takeda Pharmaceutical,.
20.9. CSL Behring,.
20.10. Vertex Pharmaceuticals,
20.11. Amgen,,
20.12. Sanofi,.
20.13. GlaxoSmithKline,,.
20.14. Gilead Sciences,.
20.15. Eli Lilly,.
20.16. AbbVie,,.
20.17. Johnson & Johnson,,.
20.18. Teva Pharmaceutical,,.
20.19. Audentes Therapeutics,,
20.20. Regeneron Pharmaceuticals,,
21. Research Methodology
21.1. Research Methodology
21.2. Patient Education – Secondary Research
21.3. Patient EducationI – Data Modelling
21.3.1. Company Share Analysis Model
21.3.2. Revenue Based Modelling
21.4. Patient EducationII – Primary Research
21.5. Research Limitations
21.5.1. Assumptions

List of Figures
FIG. 1 Global Alpha 1 Lung Disease Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Alpha 1 Lung Disease Market Segmentation
FIG. 4 Global Alpha 1 Lung Disease Market, By Diagnostics, 2022 (US$ Mn)
FIG. 5 Global Alpha 1 Lung Disease Market, By Treatments, 2022 (US$ Mn)
FIG. 6 Global Alpha 1 Lung Disease Market, By Patient Support and Services, 2022 (US$ Mn)
FIG. 7 Global Alpha 1 Lung Disease Market, by Research and Development, 2022 (US$ Mn)
FIG. 8 Global Alpha 1 Lung Disease Market, By End Users, 2022 (US$ Mn)
FIG. 9 Global Alpha 1 Lung Disease Market, by Geography, 2022 (US$ Mn)
FIG. 10 Attractive Investment Proposition, By Diagnostics, 2022
FIG. 11 Attractive Investment Proposition, By Treatments, 2022
FIG. 12 Attractive Investment Proposition, By Patient Support and Services, 2022
FIG. 13 Attractive Investment Proposition, By Research and Development, 2022
FIG. 14 Attractive Investment Proposition, By End Users, 2022
FIG. 15 Attractive Investment Proposition, by Geography, 2022
FIG. 16 Global Market Share Analysis of Key Alpha 1 Lung Disease Market Manufacturers, 2022
FIG. 17 Global Market Positioning of Key Alpha 1 Lung Disease Market Manufacturers, 2022
FIG. 18 Global Alpha 1 Lung Disease Market Value Contribution, By Diagnostics, 2022 & 2030 (Value %)
FIG. 19 Global Alpha 1 Lung Disease Market, by GENETIC TESTING, Value, 2017-2030 (US$ Mn)
FIG. 20 Global Alpha 1 Lung Disease Market, by Pulmonary Function Testing (PFT), Value, 2017-2030 (US$ Mn)
FIG. 21 Global Alpha 1 Lung Disease Market, by Liver Function Testing, Value, 2017-2030 (US$ Mn)
FIG. 22 Global Alpha 1 Lung Disease Market, by Imaging, Value, 2017-2030 (US$ Mn)
FIG. 23 Global Alpha 1 Lung Disease Market Value Contribution, By Treatments, 2022 & 2030 (Value %)
FIG. 24 Global Alpha 1 Lung Disease Market, by Alpha-1 Augmentation Therapy, Value, 2017-2030 (US$ Mn)
FIG. 25 Global Alpha 1 Lung Disease Market, by Bronchodilators, Value, 2017-2030 (US$ Mn)
FIG. 26 Global Alpha 1 Lung Disease Market, by Anti-inflammatory Drugs, Value, 2017-2030 (US$ Mn)
FIG. 27 Global Alpha 1 Lung Disease Market, by Supplemental Oxygen, Value, 2017-2030 (US$ Mn)
FIG. 28 Global Alpha 1 Lung Disease Market, by Pulmonary Rehabilitation, Value, 2017-2030 (US$ Mn)
FIG. 29 Global Alpha 1 Lung Disease Market, by Liver Disease Management, Value, 2017-2030 (US$ Mn)
FIG. 30 Global Alpha 1 Lung Disease Market Value Contribution, By Patient Support and Services, 2022 & 2030 (Value %)
FIG. 31 Global Alpha 1 Lung Disease Market, by Patient Education, Value, 2017-2030 (US$ Mn)
FIG. 32 Global Alpha 1 Lung Disease Market, by Patient Advocacy Organizations, Value, 2017-2030 (US$ Mn)
FIG. 33 Global Alpha 1 Lung Disease Market, by Telehealth and Remote Monitoring, Value, 2017-2030 (US$ Mn)
FIG. 34 Global Alpha 1 Lung Disease Market, by Psychosocial Support, Value, 2017-2030 (US$ Mn)
FIG. 35 Global Alpha 1 Lung Disease Market, by Home Healthcare Services, Value, 2017-2030 (US$ Mn)
FIG. 36 Global Alpha 1 Lung Disease Market Value Contribution, By Research and Development, 2022 & 2030 (Value %)
FIG. 37 Global Alpha 1 Lung Disease Market, by Drug Development, Value, 2017-2030 (US$ Mn)
FIG. 38 Global Alpha 1 Lung Disease Market, by Clinical Trials, Value, 2017-2030 (US$ Mn)
FIG. 39 Global Alpha 1 Lung Disease Market, by Genetic Research, Value, 2017-2030 (US$ Mn)
FIG. 40 Global Alpha 1 Lung Disease Market Value Contribution, By End Users, 2022 & 2030 (Value %)
FIG. 41 Global Alpha 1 Lung Disease Market, by Hospitals and Clinics, Value, 2017-2030 (US$ Mn)
FIG. 42 Global Alpha 1 Lung Disease Market, by Pharmaceutical Companies, Value, 2017-2030 (US$ Mn)
FIG. 43 Global Alpha 1 Lung Disease Market, by Patient Community, Value, 2017-2030 (US$ Mn)
FIG. 44 Global Alpha 1 Lung Disease Market, by Research Institutions, Value, 2017-2030 (US$ Mn)
FIG. 45 North America Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 46 U.S. Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 47 Canada Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 48 Mexico Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 49 Europe Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 50 Germany Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 51 France Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 52 U.K. Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 53 Italy Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 54 Spain Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 55 Benelux Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 56 Russia Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 57 Rest of Europe Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 58 Asia Pacific Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 59 China Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 60 Japan Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 61 India Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 62 South Korea Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 63 South-East Asia Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 64 Rest of Asia Pacific Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 65 Latin America Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 66 Brazil Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 67 Argentina Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 68 Rest of Latin America Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 69 Middle East Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 70 UAE Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 71 Saudi Arabia Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 72 Rest of Middle East Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 73 Africa Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 74 South Africa Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 75 Egypt Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)
FIG. 76 Rest of Africa Alpha 1 Lung Disease Market, 2017-2030 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Alpha 1 Lung Disease Market
TABLE 2 Global Alpha 1 Lung Disease Market: Drivers Impact Analysis
TABLE 3 Global Alpha 1 Lung Disease Market: Market Restraints Impact Analysis
TABLE 4 Global Alpha 1 Lung Disease Market, by Competitive Benchmarking, 2022
TABLE 5 Global Alpha 1 Lung Disease Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Alpha 1 Lung Disease Market, by Key Strategies Analysis, 2022
TABLE 7 Global Alpha 1 Lung Disease Market, by Genetic Testing, By Region, 2017-2022 (US$ Mn)
TABLE 8 Global Alpha 1 Lung Disease Market, by Genetic Testing, By Region, 2023-2030 (US$ Mn)
TABLE 9 Global Alpha 1 Lung Disease Market, by Pulmonary Function Testing (PFT), By Region, 2017-2022 (US$ Mn)
TABLE 10 Global Alpha 1 Lung Disease Market, by Pulmonary Function Testing (PFT), By Region, 2023-2030 (US$ Mn)
TABLE 11 Global Alpha 1 Lung Disease Market, by Liver Function Testing, By Region, 2017-2022 (US$ Mn)
TABLE 12 Global Alpha 1 Lung Disease Market, by Liver Function Testing, By Region, 2023-2030 (US$ Mn)
TABLE 13 Global Alpha 1 Lung Disease Market, by Imaging, By Region, 2017-2022 (US$ Mn)
TABLE 14 Global Alpha 1 Lung Disease Market, by Imaging, By Region, 2023-2030 (US$ Mn)
TABLE 15 Global Alpha 1 Lung Disease Market, by Alpha-1 Augmentation Therapy, By Region, 2017-2022 (US$ Mn)
TABLE 16 Global Alpha 1 Lung Disease Market, by Alpha-1 Augmentation Therapy, By Region, 2023-2030 (US$ Mn)
TABLE 17 Global Alpha 1 Lung Disease Market, by Bronchodilators, By Region, 2017-2022 (US$ Mn)
TABLE 18 Global Alpha 1 Lung Disease Market, by Bronchodilators, By Region, 2023-2030 (US$ Mn)
TABLE 19 Global Alpha 1 Lung Disease Market, by Anti-inflammatory Drugs, By Region, 2017-2022 (US$ Mn)
TABLE 20 Global Alpha 1 Lung Disease Market, by Anti-inflammatory Drugs, By Region, 2023-2030 (US$ Mn)
TABLE 21 Global Alpha 1 Lung Disease Market, by Supplemental Oxygen, By Region, 2017-2022 (US$ Mn)
TABLE 22 Global Alpha 1 Lung Disease Market, by Supplemental Oxygen, By Region, 2023-2030 (US$ Mn)
TABLE 23 Global Alpha 1 Lung Disease Market, by Pulmonary Rehabilitation, By Region, 2017-2022 (US$ Mn)
TABLE 24 Global Alpha 1 Lung Disease Market, by Pulmonary Rehabilitation, By Region, 2023-2030 (US$ Mn)
TABLE 25 Global Alpha 1 Lung Disease Market, by Liver Disease Management, By Region, 2017-2022 (US$ Mn)
TABLE 26 Global Alpha 1 Lung Disease Market, by Liver Disease Management, By Region, 2023-2030 (US$ Mn)
TABLE 27 Global Alpha 1 Lung Disease Market, by Patient Education, By Region, 2017-2022 (US$ Mn)
TABLE 28 Global Alpha 1 Lung Disease Market, by Patient Education, By Region, 2023-2030 (US$ Mn)
TABLE 29 Global Alpha 1 Lung Disease Market, by Patient Advocacy Organizations, By Region, 2017-2022 (US$ Mn)
TABLE 30 Global Alpha 1 Lung Disease Market, by Patient Advocacy Organizations, By Region, 2023-2030 (US$ Mn)
TABLE 31 Global Alpha 1 Lung Disease Market, by Telehealth and Remote Monitoring, By Region, 2017-2022 (US$ Mn)
TABLE 32 Global Alpha 1 Lung Disease Market, by Telehealth and Remote Monitoring, By Region, 2023-2030 (US$ Mn)
TABLE 33 Global Alpha 1 Lung Disease Market, by Psychosocial Support, By Region, 2017-2022 (US$ Mn)
TABLE 34 Global Alpha 1 Lung Disease Market, by Psychosocial Support, By Region, 2023-2030 (US$ Mn)
TABLE 35 Global Alpha 1 Lung Disease Market, by Home Healthcare Services, By Region, 2017-2022 (US$ Mn)
TABLE 36 Global Alpha 1 Lung Disease Market, by Home Healthcare Services, By Region, 2023-2030 (US$ Mn)
TABLE 37 Global Alpha 1 Lung Disease Market, by Drug Development, By Region, 2017-2022 (US$ Mn)
TABLE 38 Global Alpha 1 Lung Disease Market, by Drug Development, By Region, 2023-2030 (US$ Mn)
TABLE 39 Global Alpha 1 Lung Disease Market, by Clinical Trials, By Region, 2017-2022 (US$ Mn)
TABLE 40 Global Alpha 1 Lung Disease Market, by Clinical Trials, By Region, 2023-2030 (US$ Mn)
TABLE 41 Global Alpha 1 Lung Disease Market, by Genetic Research, By Region, 2017-2022 (US$ Mn)
TABLE 42 Global Alpha 1 Lung Disease Market, by Genetic Research, By Region, 2023-2030 (US$ Mn)
TABLE 43 Global Alpha 1 Lung Disease Market, by Hospitals and Clinics, By Region, 2017-2022 (US$ Mn)
TABLE 44 Global Alpha 1 Lung Disease Market, by Hospitals and Clinics, By Region, 2023-2030 (US$ Mn)
TABLE 45 Global Alpha 1 Lung Disease Market, by Pharmaceutical Companies, By Region, 2017-2022 (US$ Mn)
TABLE 46 Global Alpha 1 Lung Disease Market, by Pharmaceutical Companies, By Region, 2023-2030 (US$ Mn)
TABLE 47 Global Alpha 1 Lung Disease Market, by Patient Community, By Region, 2017-2022 (US$ Mn)
TABLE 48 Global Alpha 1 Lung Disease Market, by Patient Community, By Region, 2023-2030 (US$ Mn)
TABLE 49 Global Alpha 1 Lung Disease Market, by Research Institutions, By Region, 2017-2022 (US$ Mn)
TABLE 50 Global Alpha 1 Lung Disease Market, by Research Institutions, By Region, 2023-2030 (US$ Mn)
TABLE 51 Global Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 52 Global Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 53 Global Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 54 Global Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 55 Global Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 56 Global Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 57 Global Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 58 Global Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 59 Global Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 60 Global Alpha 1 Lung Disease Market, by Region, 2017-2022 (US$ Mn)
TABLE 61 Global Alpha 1 Lung Disease Market, by Region, 2023-2030 (US$ Mn)
TABLE 62 North America Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 63 North America Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 64 North America Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 65 North America Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 66 North America Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 67 North America Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 68 North America Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 69 North America Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 70 North America Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 71 North America Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 72 North America Alpha 1 Lung Disease Market, by Country, 2017-2022 (US$ Mn)
TABLE 73 North America Alpha 1 Lung Disease Market, by Country, 2023-2030 (US$ Mn)
TABLE 74 United States Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 75 United States Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 76 United States Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 77 United States Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 78 United States Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 79 United States Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 80 United States Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 81 United States Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 82 United States Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 83 United States Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 84 Canada Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 85 Canada Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 86 Canada Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 87 Canada Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 88 Canada Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 89 Canada Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 90 Canada Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 91 Canada Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 92 Canada Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 93 Canada Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 94 Mexico Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 95 Mexico Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 96 Mexico Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 97 Mexico Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 98 Mexico Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 99 Mexico Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 100 Mexico Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 101 Mexico Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 102 Mexico Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 103 Mexico Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 104 Europe Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 105 Europe Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 106 Europe Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 107 Europe Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 108 Europe Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 109 Europe Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 110 Europe Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 111 Europe Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 112 Europe Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 113 Europe Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 114 Europe Alpha 1 Lung Disease Market, by Country, 2017-2022 (US$ Mn)
TABLE 115 Europe Alpha 1 Lung Disease Market, by Country, 2023-2030 (US$ Mn)
TABLE 116 Germany Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 117 Germany Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 118 Germany Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 119 Germany Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 120 Germany Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 121 Germany Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 122 Germany Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 123 Germany Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 124 Germany Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 125 Germany Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 126 France Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 127 France Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 128 France Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 129 France Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 130 France Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 131 France Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 132 France Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 133 France Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 134 France Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 135 France Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 136 United Kingdom Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 137 United Kingdom Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 138 United Kingdom Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 139 United Kingdom Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 140 United Kingdom Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 141 United Kingdom Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 142 United Kingdom Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 143 United Kingdom Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 144 United Kingdom Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 145 United Kingdom Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 146 Italy Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 147 Italy Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 148 Italy Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 149 Italy Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 150 Italy Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 151 Italy Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 152 Italy Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 153 Italy Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 154 Italy Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 155 Italy Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 156 Spain Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 157 Spain Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 158 Spain Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 159 Spain Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 160 Spain Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 161 Spain Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 162 Spain Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 163 Spain Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 164 Spain Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 165 Spain Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 166 Benelux Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 167 Benelux Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 168 Benelux Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 169 Benelux Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 170 Benelux Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 171 Benelux Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 172 Benelux Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 173 Benelux Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 174 Benelux Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 175 Benelux Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 176 Russia Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 177 Russia Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 178 Russia Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 179 Russia Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 180 Russia Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 181 Russia Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 182 Russia Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 183 Russia Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 184 Russia Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 185 Russia Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 186 Rest of Europe Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 187 Rest of Europe Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 188 Rest of Europe Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 189 Rest of Europe Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 190 Rest of Europe Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 191 Rest of Europe Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 192 Rest of Europe Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 193 Rest of Europe Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 194 Rest of Europe Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 195 Rest of Europe Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 196 Asia Pacific Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 197 Asia Pacific Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 198 Asia Pacific Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 199 Asia Pacific Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 200 Asia Pacific Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 201 Asia Pacific Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 202 Asia Pacific Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 203 Asia Pacific Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 204 Asia Pacific Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 205 Asia Pacific Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 206 China Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 207 China Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 208 China Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 209 China Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 210 China Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 211 China Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 212 China Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 213 China Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 214 China Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 215 China Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 216 Japan Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 217 Japan Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 218 Japan Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 219 Japan Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 220 Japan Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 221 Japan Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 222 Japan Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 223 Japan Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 224 Japan Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 225 Japan Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 226 India Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 227 India Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 228 India Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 229 India Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 230 India Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 231 India Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 232 India Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 233 India Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 234 India Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 235 India Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 236 South Korea Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 237 South Korea Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 238 South Korea Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 239 South Korea Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 240 South Korea Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 241 South Korea Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 242 South Korea Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 243 South Korea Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 244 South Korea Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 245 South Korea Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 246 South-East Asia Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 247 South-East Asia Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 248 South-East Asia Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 249 South-East Asia Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 250 South-East Asia Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 251 South-East Asia Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 252 South-East Asia Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 253 South-East Asia Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 254 South-East Asia Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 255 South-East Asia Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 256 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 257 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 258 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 259 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 260 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 261 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 262 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 263 Rest of Asia Pacific Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 264 Rest of Asia Pacific Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 265 Rest of Asia Pacific Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 266 Latin America Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 267 Latin America Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 268 Latin America Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 269 Latin America Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 270 Latin America Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 271 Latin America Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 272 Latin America Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 273 Latin America Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 274 Latin America Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 275 Latin America Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 276 Brazil Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 277 Brazil Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 278 Brazil Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 279 Brazil Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 280 Brazil Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 281 Brazil Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 282 Brazil Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 283 Brazil Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 284 Brazil Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 285 Brazil Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 286 Argentina Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 287 Argentina Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 288 Argentina Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 289 Argentina Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 290 Argentina Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 291 Argentina Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 292 Argentina Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 293 Argentina Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 294 Argentina Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 295 Argentina Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 296 Rest of Latin America Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 297 Rest of Latin America Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 298 Rest of Latin America Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 299 Rest of Latin America Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 300 Rest of Latin America Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 301 Rest of Latin America Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 302 Rest of Latin America Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 303 Rest of Latin America Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 304 Rest of Latin America Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 305 Rest of Latin America Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 306 Middle East Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 307 Middle East Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 308 Middle East Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 309 Middle East Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 310 Middle East Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 311 Middle East Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 312 Middle East Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 313 Middle East Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 314 Middle East Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 315 Middle East Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 316 UAE Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 317 UAE Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 318 UAE Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 319 UAE Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 320 UAE Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 321 UAE Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 322 UAE Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 323 UAE Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 324 UAE Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 325 UAE Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 326 Saudi Arabia Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 327 Saudi Arabia Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 328 Saudi Arabia Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 329 Saudi Arabia Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 330 Saudi Arabia Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 331 Saudi Arabia Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 332 Saudi Arabia Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 333 Saudi Arabia Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 334 Saudi Arabia Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 335 Saudi Arabia Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 336 Rest of Middle East Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 337 Rest of Middle East Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 338 Rest of Middle East Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 339 Rest of Middle East Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 340 Rest of Middle East Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 341 Rest of Middle East Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 342 Rest of Middle East Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 343 Rest of Middle East Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 344 Rest of Middle East Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 345 Rest of Middle East Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 346 Africa Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 347 Africa Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 348 Africa Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 349 Africa Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 350 Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 351 Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 352 Africa Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 353 Africa Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 354 Africa Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 355 Africa Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 356 South Africa Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 357 South Africa Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 358 South Africa Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 359 South Africa Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 360 South Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 361 South Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 362 South Africa Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 363 South Africa Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 364 South Africa Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 365 South Africa Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 366 Egypt Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 367 Egypt Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 368 Egypt Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 369 Egypt Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 370 Egypt Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 371 Egypt Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 372 Egypt Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 373 Egypt Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 374 Egypt Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 375 Egypt Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)
TABLE 376 Rest of Africa Alpha 1 Lung Disease Market, By Diagnostics, 2017-2022 (US$ Mn)
TABLE 377 Rest of Africa Alpha 1 Lung Disease Market, By Diagnostics, 2023-2030 (US$ Mn)
TABLE 378 Rest of Africa Alpha 1 Lung Disease Market, By Treatments, 2017-2022 (US$ Mn)
TABLE 379 Rest of Africa Alpha 1 Lung Disease Market, By Treatments, 2023-2030 (US$ Mn)
TABLE 380 Rest of Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2017-2022 (US$ Mn)
TABLE 381 Rest of Africa Alpha 1 Lung Disease Market, By Patient Support and Services, 2023-2030 (US$ Mn)
TABLE 382 Rest of Africa Alpha 1 Lung Disease Market, By Research and Development, By Region, 2017-2022 (US$ Mn)
TABLE 383 Rest of Africa Alpha 1 Lung Disease Market, By Research and Development, By Region, 2023-2030 (US$ Mn)
TABLE 384 Rest of Africa Alpha 1 Lung Disease Market, By End Users, 2017-2022 (US$ Mn)
TABLE 385 Rest of Africa Alpha 1 Lung Disease Market, By End Users, 2023-2030 (US$ Mn)

What is the current size of the global Alpha 1 Lung Disease Market?

The global Alpha 1 Lung Disease Market was valued at USD 5184.5 Million in 2022.

What is the expected growth rate of the Alpha 1 Lung Disease Market between 2023 and 2030?

The Alpha 1 Lung Disease Market is expected to grow at a CAGR of 19.50% between 2023 and 2030, reaching USD 21560.0 Million in 2030.

Which segment is leading the market share in terms of End Users?

The hospital and clinic segment dominates the market

Which region is fueling the growth of the Alpha 1 Lung Disease industry?

North America is likely to be the largest market during the forecast period, accounting for more than 45% of the market share in 2022

Qatar Dental Care Market

Published:
Report ID: 30608

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Hepatic Encephalopathy Market

Published:
Report ID: 33664

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Guidewires Market

Published:
Report ID: 6790

3D Printing for Personalized Healthcare Market

Published:
Report ID: 33603

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

In Vitro Diagnostic (IVD) Kit Market

Published:
Report ID: 33580

North America Medical Headgears Market

Published:
Report ID: 33554

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN